Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11439669
C. novyi for the treatment of solid tumors in humans
granted -
US 11440907
Antiproliferation compounds and uses thereof
granted -
US 11440950
Anti-VEGF protein compositions and methods for producing the same
granted -
US 11440956
Anti-thyroglobulin T cell receptors
granted -
US 11440963
Combination PDL1 and TGF-beta blockade in patients with HPV+ malignancies
granted -
US 11447498
Fused tetracyclic compounds and uses thereof in medicine
granted -
US 11446323
Compositions and methods for the treatment of fibrotic diseases
granted -
US 11446353
Compositions and methods for the treatment of fungal infections
granted -
US 11446360
High-purity inhalable particles of insulin and insulin analogues, and high-efficiency methods of manufacturing the same
granted -
US 11447488
Heterocyclic compounds
granted -
US 11446397
Gene therapy vectors for treating heart disease
granted -
US 11446389
Maytansinoid derivatives, conjugates thereof, and methods of use
granted -
US 11446385
Polymer derivatives having particular atom arrangements
granted -
US 11447453
Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
granted -
US 11447541
Anti-coronavirus antibodies and methods of use
granted -
US 11450420
Secure smart dosing system with automated delivery, measurement, and management for pills
granted -
US 11446383
Lipid formulations for delivery of therapeutic agents
granted -
US 11446365
Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
granted -
US 11446380
Compositions and methods for inhibition of HAO1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
granted -
US 11446357
Method for treating disease using FOXP3+CD4+ T cells
granted -
US 11446342
Composite probiotics and use thereof
granted -
US 11446332
Combinatorial cancer immunotherapy
granted -
US 11445997
Ultrasound imaging of biomarker sensitive hydrogels
granted -
US 11447797
AAV with unique capsid protein VP1 and methods of using for treatment
granted -
US 11447573
Multispecific antigen binding proteins and methods of use thereof
granted -
US 11447537
PDL2 compounds
granted -
US 11447830
Gene signatures to predict drug response in cancer
granted -
US 11447563
Tumor selective macropinocytosis-dependent rapidly internalizing antibodies
granted -
US 11447753
Non-neuroinvasive viruses and uses thereof
granted -
US 11447508
Heteroaromatic silicon-fluoride-acceptors useful for 18F labeling of molecules and biomolecules, and methods of preparing same
granted -
US 11447510
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
granted -
US 11447500
Thienopyridine derivatives and pharmaceutical composition comprising same
granted -
US 11447521
Compounds and methods for modulating angiotensinogen expression
granted -
US 11446331
Wound healing and tissue engineering
granted -
US 11446310
Stable formulations for parenteral injection of small molecule drugs
granted -
US 11446302
Compounds with anti-tumor activity against cancer cells bearing EGFR or HER2 exon 20 mutations
granted -
US 11446279
Aromatic 2-nitrosulfonyl fluoride antibiotics and methods of use thereof
granted -
US 11446271
Methods and compositions for increasing the potency of antifungal agents
granted -
US 11446253
Ionic liquids for internal delivery
granted -
US 11447452
Agonists of peroxisome proliferator-activated receptor alpha and methods of use
granted -
US 11446238
Injectable dendrimer hydrogel nanoparticles
granted -
AU 2021233167
Compositions improving poxvirus stability
granted -
US 11453702
Bicyclic peptide ligands specific for Nectin-4
granted -
US 11453703
Heterotandem bicyclic peptide complexes
granted -
US 11453714
Human antibodies to influenza hemagglutinin
granted -
US 11453719
Compositions and methods for treating cancer with anti-ROR1 immunotherapy
granted -
US 11453721
Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
granted -
US 11453725
Methods for DNA-dependent targeting of a cell permeant antibody
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.